Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy

Next Previous
X
Search
Trial Profile

A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dactolisib (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 19 Apr 2016 No of arms changed from 2 to 1 in which placebo arm is removed as per ClinicalTrials.gov record.
    • 01 Feb 2016 Results of an interim futility analysis published in the Anticancer Research
    • 01 Feb 2016 Primary endpoint has not been met. (Stage 1 - Progression Free Survival (PFS) at 16 weeks) as per the results published in the Anticancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top